American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
← All editions
Following a story · 2 updates

FTC finalizes insulin antitrust settlement with CVS Caremark

Jul 15, 2026 – Aug 1, 2026

  1. Jul 15, 2026 The Ledger Enforcement

    FTC settles insulin pricing antitrust case with CVS Caremark for up to $8.5 billion in savings

    The FTC settled its antitrust case against CVS Caremark over rebating practices it said inflated insulin list prices, securing up to 8.5 billion dollars in projected consumer savings over 10 years and a new 25 dollar monthly insulin cap program.

    Read this issue →
  2. Aug 1, 2026 The Service Line Enforcement Latest

    FTC finalizes insulin antitrust settlement with CVS Caremark

    The FTC's July 14, 2026 order bars Caremark from disadvantaging low list price insulin, requires a rebate pass through option, and projects up to 8.5 billion dollars in patient savings over 10 years, leaving Optum Rx as the only Big Three PBM without a final order.

    Read this issue →